Organon & Co. (OGN)
| Market Cap | 8.54B |
| Revenue (ttm) | 7.89B |
| Net Income (ttm) | n/a |
| Shares Out | 253.52M |
| EPS (ttm) | 6.86 |
| PE Ratio | 4.91 |
| Forward PE | 5.03 |
| Dividend | $1.12 (3.32%) |
| Ex-Dividend Date | Aug 20, 2021 |
| Volume | 1,888,126 |
| Open | 33.50 |
| Previous Close | 33.38 |
| Day's Range | 33.00 - 33.95 |
| 52-Week Range | 27.03 - 38.75 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 41.80 (+24.1%) |
| Est. Earnings Date | Nov 11, 2021 |
About OGN
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Ca...
Financial Performance
In 2020, Organon's revenue was $8.10 billion, a decrease of -15.05% compared to the previous year's $9.53 billion. Earnings were $2.16 billion, a decrease of -32.88%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for Organon stock is "Buy." The 12-month stock price forecast is 41.80, which is an increase of 24.07% from the latest price.
News
Organon Aims to Ignite Worldwide Conversation Around Unplanned Pregnancy
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon issues Public Service Announcement inviting women to ignite a global conversation on unplanned pregnancy.
3 Reasons To Buy Organon Stock, Says BofA Analyst
Organon & Co (NYSE:OGN), which has recently spun-off from Merck & Co., Inc. (NYSE:MRK), has “inherited a global business across three segments,” namely Women's Health, Legacy and Biosimilars brands, acc...
Organon To Present at Morgan Stanley's 19th Annual Global Healthcare Virtual Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a ...
Organon To Present at Citi's 16th Annual BioPharma Virtual Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a ...
Avestria Ventures Closes Fund I
SAN FRANCISCO--(BUSINESS WIRE)-- #femalefounders--Avestria Ventures closes Fund I. The Bay Area-based venture capital firm invests in women's health and female-led life science ventures.
Jeff Auxier Discloses Position in Organon, Curbs Several Top Holdings
Auxier Asset Management leader Jeff Auxier (Trades, Portfolio) released his second-quarter portfolio last week.
Top Stocks Warren Buffett Just Bought
These were Berkshire Hathaway's biggest buys during Q2, 2021.
GuruFocus Announces Winner of 2nd-Quarter Warren Buffett Contest
GuruFocus is proud to announce that there was one winner of the second-quarter Warren Buffett (Trades, Portfolio) contest: Steak.
Warren Buffett Sells Biotech Holdings After a Year
Yesterday, Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial)( BRK.B , Financial) published its 13F report for the period ending June 30.
Buffett Adds More Kroger, Welcomes Organon in Q2
Berkshire Hathaway's latest 13F filing revealed Warren Buffett sold plenty of stocks in Q2 2021, but added to his Kroger position and gained a "new" stake in Merck spin-off Organon.
Organon Stock Jumps On Profit Beat In First Post-Spinoff Report
Total revenue of $1.6 billion grew by a modest 4.5% YOY (-1% excluding foreign currency impact or excl.fx) reflecting the impact of loss of exclusivity on some products, but beat consensus by 5.2%.
Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates
Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.
Organon Reports Results for the Second Quarter Ended June 30, 2021 and Announces Inaugural Dividend
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN) (the “company”), today announced its results for the second quarter and year to date ended June 30, 2021 and affirmed its full year 2021...
5 Undervalued Stocks Popular Among Gurus
GuruFocus' Most Broadly Held model portfolio consists of the 25 stocks that have the highest number of guru owners, rebalanced annually.
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigationa...
JERSEY CITY, N.J. & GENEVA, Switzerland--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), a global women's health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to i...
Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021
3 Stocks I'd Avoid at All Costs
On the surface, these companies seem like underpriced investments, but look a little closer and there's a good reason to stay away.
Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?
Neither healthcare stock has performed well so far this year.
Stay Away From Low-Growth Organon
Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive. The post Stay Away From Low-Growth Organon appeared first on InvestorPlace.
Spinoffs Roundup: These Companies Could Unlock Value in 2021
Some spinoffs can unlock the true value of businesses by allowing them to focus on their niches better than being part of a bulkier multi-faceted corporation allows. On the other hand, some spinoffs are...
Why Merck's Organon Spinoff Could Be Worth Billions
Don't think of Merck spinoff Organon as a research engine. The new pharmaceutical stock is a pure-play commercial entity.
Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
Don't Miss the Opportunity Presented by Organon Stock
If a company's spun off from a pharmaceutical giant, you'd think the buzz about it would be deafening. Yet OGN stock remains an underappreciated gem.
Organon Announces Filing of Form 10-Q for the Quarter Ended March 31, 2021
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Announces Filing of Form 10-Q for the quarter ended March 31, 2021